AFF1 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains ELL status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [3].